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Background: Pancreatic cancer development is associated with characteristic alterations like desmoplastic reaction
and immune escape which are mediated by the cell-cell communication mechanism and by the microenvironment of
the cells. The whole of released components are important determinants in these processes. Especially the extracellular
vesicles released by pancreatic cancer cells play a role in cell communication and modulate cell growth and immune
responses.
Results: Here, we present the proteomic description of affinity purified extracellular vesicles from pancreatic tumour
cells, compared to the secretome, defined as the whole of the proteins released by pancreatic cancer cells. The
proteomic data provide comprehensive catalogues of hundreds of proteins, and the comparison reveals a special
proteomic composition of pancreatic cancer cell derived extracellular vesicles. The functional analysis of the protein
composition displayed that membrane proteins, glycoproteins, small GTP binding proteins and a further,
heterogeneous group of proteins are enriched in vesicles, whereas proteins derived from proteasomes and ribosomes,
as well as metabolic enzymes, are not components of the vesicles. Furthermore proteins playing a role in
carcinogenesis and modulators of the extracellular matrix (ECM) or cell-cell interactions are components of affinity
purified extracellular vesicles.
Conclusion: The data deepen the knowledge of extracellular vesicle composition by hundreds of proteins that have
not been previously described as vesicle components released by pancreatic cancer cells. Extracellular vesicles derived
from pancreatic cancer cells show common proteins shared with other vesicles as well as cell type specific proteins
indicating biomarker candidates and suggesting functional roles in cancer cell stroma interactions.
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Pancreatic cancer is the fifth most common cancer-related
cause of death in Europe [1] and one of the most aggres-
sive forms of human cancer. The diagnoses occur only at
late stages when the patients have developed metastases,
and the five-year survival rate of patients is only 5%. Up
until now it has not been possible to decide whether the
metastatic ability is a characteristic of the pancreatic can-
cer cell, or whether this is due to the delayed diagnosis.* Correspondence: susanne.klein-scory@rub.de
1IMBL, Medical Clinic Knappschaftskrankenhaus Bochum GmbH,
Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany
Full list of author information is available at the end of the article
© 2014 Klein-Scory et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.Pancreatic cancer often develops after or during pancre-
atic inflammation, and the differential diagnosis is com-
plex [2]. There is an urgent need to find early and
specific pancreatic cancer biomarkers, and it is neces-
sary to develop further strategies for the treatment of this
fatal disease; thus far, no curative therapies are available.
Therefore, each biomarker discovery approach for pancre-
atic cancer should also pay attention to therapeutic impli-
cations and functional roles.
The development of pancreatic cancer is accompanied
by some characteristic events: the ability to escape im-
mune responses, the attraction of stroma cells in the des-
moplastic reaction, the intravasative capacity of pancreatictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.proteomesci.com/content/12/1/50cancer cells, and the low vascularization of pancreatic tu-
mours, as well as the frequently found thromboses [3].
These characteristic processes are mediated by mecha-
nisms of intercellular communication and by the micro-
environment of the cells.
To deepen the understanding of these processes, our
group and others have used the conditioned medium of
cancer cells. This conditioned medium, or secretome, of
cancer cells contains the whole of the released proteins of
the cells, including regularly and aberrantly processed pro-
teins. Consequently, the entirety of the released proteins is
considered to be a discovery platform for the identification
of tumour biomarker candidates [4]. There are different
mechanisms to release proteins from cells, such as classical
secretion and exocytosis, shedding by proteolytic activities,
unspecific release by apoptosis, and the release of small
vesicles [5]. The extracellular microvesicles (EVs) are re-
leased from most normal, diseased and neoplastic cells,
and EVs are found in different body fluids, like plasma, as-
cites fluid, urine and saliva, and used to identify biomarkers
of diseases [6]. However, in these approaches, the identity
and origin of the vesicles are usually not exactly clarified,
and EVs are prepared in different ways [7].
Over the last few years, EVs have increasingly become
the focus of different research studies, and the current
knowledge about EVs is summarized in some recent re-
views [8-10]. Different EVs should play a prominent role
in cell communication performing manifold functions.
They facilitate invasion, modulate the mechanisms of
thrombosis, can induce chemoresistance, and are media-
tors of immune surveillance (reviewed in [11]). The re-
leased vesicles mediate the ability of tumour cells to alter
the environment, and help the cells during invasion or at-
tachment to the extracellular matrix. These functions of
EVs are executed by the diverse constituent molecules,
and the elucidation of the composition of these vesicles is
of major interest. Recent publications have shown that
EVs contain specific proteins, like CD63/Lamp3, CD9 and
SDCBP/Syntenin, and ribonucleic acid instrumentations
[12,13]. Proteomic description of EVs of tumour cell types,
especially from colon, breast, head and neck, prostate can-
cers and melanoma, have been published ([6] and special
issue in Proteomics, 2013), but in depth information about
pancreatic carcinoma cell derived EVs is not available so
far. To close this gap, the present manuscript is going to
describe the protein content of the EVs of pancreatic cells,
and combine this information with postulated functions
or assigned tasks in pancreatic carcinogenesis [14].
Results
Extracellular vesicles preparations obtained via
ultracentrifugation are not pure vesicular samples
For the sample preparations, the conditioned media were
prepared and subjected to a differential centrifugationprotocol as described in the Materials and Methods sec-
tion. The conditioned media were collected from serum
free cultures, in order to avoid the contamination of the
samples with calf serum components, such as albumins
and bovine EVs. The secretome samples of the pancreatic
cells contained about 5–20 μg protein per 106 cells, and
the crude pellet after the centrifugation procedure con-
tained only about 0.2-0.4 μg protein per 106 cells.
The characteristic proteins (compiled in [15]) for the
EVs like syntenin, CD9, CD63 and Alix revealed an en-
richment of EVs in these crude preparations as com-
pared to the secretome and cell lysates (Figure 1a). Some
of the EV marker proteins, such as CD9 or Syntenin, are
more than twentyfold enriched in the ultracentrifugation
samples when compared to the secretomes or cell ly-
sates. Furthermore, the ultracentrifugation pellets were
subjected to an OptiPrep gradient centrifugation to test
whether the crude preparations of the vesicles corre-
sponded to the typical densities of the EVs, as described
earlier [16]. The fractions with the densities of 1.08-
1.15 g/ml contained the EV marker proteins CD63 and
syntenin (Figure 1b).
Aliquots of the crude preparations of different cells
were inspected by TEM and, in fact, the pictures
showed that the preparations contained vesicles, which
were surrounded by a lipid bilayer membrane (Figure 1c).
The vesicular content of the crude preparations was also
supported by results after detergent treatment to destroy
the lipid bilayers (Additional file 1: Figure S1a). Syntenin
and CD9 marker proteins were distributed between the
ultrafiltrate and the flow through of a 100 kDa filtration
when the samples were treated with Triton ×100 or
with a solubilisation buffer, but not after treatment with a
low pH buffer. Additionally, the labelling with the mem-
brane stain PKH67 or PKH26 delivered a picture of bright
fluorescent particles which fit to the vesicular character of
the preparations (Additional file 1: Figure S1b).
From all of these findings, we conclude that the sam-
ples produced in combination with ultracentrifugation
were suitable for analysis by mass spectrometry as a
crude vesicular preparation. However, the samples were
not pure vesicular probes, but contained further elec-
tron dense particles. To enhance the purity of our ves-
icular samples, we performed the affinity purification
discussed as the gold standard for isolating pure vesi-
cles [10,17,18].
Affinity purification is a successful procedure to enrich
extracellular vesicles
Based on the proteomic analyses of the crude vesicle prep-
arations and secretomes, we chose membrane proteins as
anchors for the affinity purification with magnetic beads.
We favoured the membrane protein TACSTD1/Epcam
to establish affinity purification of the EVs, because it is
Figure 1 EVs from pancreatic cancer cells: a) Immunoblots of different samples: proteins characteristic for EVs were enriched in pellets
(P) after ultrafiltration and ultracentrifugation, compared to secretome (Secr) or lysate samples (Ly). b) The crude extracellular vesicle
samples in an OptiPrep gradient centrifugation. The EV markers Syntenin and CD63/Lamp3 were found in fractions with densities of 1.07-1.15
g/ml as illustrated by dot blots. c) Transmission electron microscope (TEM) pictures of 120,000 g pellets of Panc1 and Paca44. Lipid bilayers
surrounding the vesicles are visible (arrowheads).
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retained in pancreas carcinoma cells [19] and has not
been reported to be altered by mutation.
We probed the secretomes and crude EV preparations
of six pancreatic ductal cell lines (Additional file 1: Figure
S2a). Based on the high amount of TACSTD1/Epcam in
the Paca44 samples which was also confirmed by mass
spec results (21 peptides in Paca44 secretome versus 8
peptides in Panc1 secretomes), Paca44 was the most suit-
able source to isolate the EVs by anti-TACSTD1/Epcam
coated beads. This cell line, established from a primary
tumour, carries the most common genotype changes oc-
curring during pancreatic carcinogenesis (mutated K-ras,
mutated p53, deleted p16Ink4a, and wildtype smad4
genes) [20]. (The ascites derived cell line A818-4 also
expressing some amount of EPCAM was disregarded
for this approach, because it is not mutated in p53 and
smad4 and because these cells can not easily be
produced in very large numbers.) As a second cell line
we selected Panc1 cells which also express some
TACSTD1/Epcam anchor protein. This cell line wasisolated from a primary tumour and also displays
genetic alterations typically found in pancreatic cancers
[20]. As expression levels of TACSTD1/Epcam were much
lower in Panc1 cells as compared to Paca44 and might
be limiting the efficiency of affinity purification, we
additionally used the membrane protein MFGE8/lac-
tadherin for purification of Panc1 derived EVs. MFGE8
displayed a very high number of peptides (286) in mass
spectrometric analyses of crude EV samples from Panc1
(but not Paca44) cells. The immune blots confirmed that
the protein MFGE8/lactadherin is overrepresented in the
Panc1 secretome and EV preparations (Additional file 1:
Figure S2b).
To prepare the affinity pure samples, we produced
the crude EV preparations and subsequently incubated
them with specific bead complexes as described below.
After affinity purification, the magnetic bead bound
fractions (eluates), as well as the unbound fractions
(flow through), were controlled by immune detection.
The eluates of Paca44 derived preparations contained
enriched amounts of the TACSTD1/Epcam and of the EV
Figure 2 Affinity purifications of EV samples: a) Using the anchor proteins of EVs TACSTD1/Epcam or MFGE8 the exosomal marker
proteins as CD9, SDCBP/Syntenin and CD63 were enriched in the eluates (El) after affinity purifications of EVs whereas no or smaller
amount of exosomal proteins were detected in flow through (FT). Samples were eluted with PBS or NP40. b) Immunoblots confirmed that
proteins like proteasome subunit alpha and tubulin beta partially remain in the flow through. c) Treatments of affinity purified samples with
detergents (Triton × 100) allowed the passage of exosomal marker proteins through the ultrafilter membrane (cut off at 100 kDa). Ret, retentate;
Fil filtrate.
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S3). Obviously, by the immune detection, the affinity puri-
fication procedure was more efficient with the Paca44
samples than with Panc1 samples using both membrane
anchors, TACSTD1/Epcam and MFGE8.
While some exosomal specific proteins were enriched
within the purified samples, other protein groups, like the
proteasome subunit proteins or tubulins, were detected in
the flow through, only. Whereas these proteins have beendescribed as components of the exosomes earlier [21],
they in fact seem to be contaminants of the crude prepa-
rations (Figure 2b).
We wished to further proof the vesicular nature of
these affinity preparations. As binding of the vesicles to
the ferromagnetic beads can barely be resolved without
destroying the vesicles, it was not possible to display the
affinity pure samples in the electron microscope. Alter-
natively, we again used a detergent treatment followed
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tween protein complexes and membrane vesicles.
Treatment with triton X 100 led to a partial release of
EV marker proteins syntenin and CD9 from the affinity-
pure samples into the flow-through (Figure 2c). In
addition, the affinity preparations were stained for mem-
brane proteins (TACSTD1/Epcam and EGFR) and ana-
lysed by FACS (data not shown). The samples prior to and
after affinity purification were labelled with fluorescence-
conjugated antibodies detecting the membrane specific
proteins, and with membrane stains like PKH67. The
fluorescence signals were reduced in the flow through
fraction of affinity purification versus the initial crude
EV samples, assuming that the flow through fraction
had been depleted of membrane vesicles.
In summary, the affinity purification procedure as de-
scribed above appears adequate to strongly reduce con-
tamination of protein complexes from real vesicular
components.
Proteomic characterization of the EV preparations
Compilation of proteomics data
The protein catalogues of the mass spectrometry results
were produced from the secretomes and crude vesicle
preparations of Panc1, Paca44 and HPDE cells and from
affinity purified EV preparations from Panc1 and Paca44
cells. In addition, a catalogue of Panc1 whole cell lysate
was available. The numbers of found proteins identified
and the mass spectrometry details are compiled in
Table 1. The complete protein catalogues compiling
4096 proteins in total are listed in an additional excel
data file (Additional file 2) and illustrated in Venn dia-
grams (Additional file 1: Figure S4a,b).
We were first interested in differences between the di-
verse compartments (secretome, crude vesicles, affinity-
purified vesicles) within one cell line. A comparison of the
protein lists from crude and affinity purified EVs and the
secretome is shown in the Venn diagrams (Figure 3). Of
note, just about the half of the proteins identified in the
affinity-pure sample of Paca44 (477 proteins) had shown
up in the crude EV sample and most of the novel protein
are not found in the secretome either, suggesting that the
depth of proteomic analysis of the EVs was significantly
increased by affinity purification.
The affinity purification of the Panc1 samples was less
effective using both anchor proteins. On the other hand,
we had more comprehensive data available for crude EV
preparations in this case. Consistently, the number of pro-
teins identified in the affinity pure samples of Panc1 EVs
was lower (415 proteins) and the overlap with the crude
sample higher (85%) as compared to Paca44 EVs.
A similar pattern of overlaps with the secretome and the
crude sample on the one hand and distinct proteins in the
affinity pure sample was detected with the sample fromMFGE8 affinity purification, which comprises 292 proteins
in total.
Interestingly, however, both catalogues of the affinity
pure samples share only 173 proteins (Additional file 1:
Figure S4c) and both affinity pure samples of Panc1 gave
535 proteins. This finding may suggest, that the affinity
purification procedures with these two anchor proteins
enrich distinct vesicle subpopulations.
Secondly, we were interested in changes of the proteomic
composition through affinity purification of vesicles com-
mon to both cell lines. Here we again present the data in
the Venn diagram; further aspects are discussed later on.
The overlap between the two different Epcam affinity
samples appears moderate at a first glance (37 and 43%, re-
spectively, in Figure 3). These lists, however, were to be
produced from very small amounts of material, only, which
restricts the analytical deapth of the analysis. Importantly,
however, the fraction of common proteins shared between
the EPCAM affinity purified sample from Paca44 cells is
reduced from 37% to just 24% with Panc1 derived vesicles,
when MFGE8 rather than Epcam is used as the anchor
protein, supporting our contention, that both anchors
may enrich different subsets of extracellular vesicles.
Comparison with exocharta and vesiclepedia
The proteomic compositions of the purified EVs from the
pancreatic cancer cells overlap partially with the data de-
scribed earlier for EVs derived from other cells [22], but
enlarge the knowledge with information about vesicles of
pancreatic tumour cell origin. This is apparent when the
table of proteins from Paca44 (as well from the Panc1
extracellular vesicle samples) is merged with the entries of
the proteins from 2013 in the Vesiclepedia version 1.1 and
ExoCarta version 4.1 database [15,22]. Both compilations
share more than 600 proteins, but more than 200 Paca44
EV proteins (120 proteins out of the Epcam pure EV pro-
teins) are not included in either database. Furthermore,
150 proteins of affinity purified Panc1 EVs (98 from
EPCAM pure and 89 proteins from MFGE8 pure EVs) are
still missing from the database (the Additional file 2: Table
S1 contains this information in cell type specific files
assigned in a separate column). Among these proteins are
many SLC proteins and other transmembrane glycopro-
teins like Claudine 12, GPR56 or PVR and related proteins
which were described as expressed by cancer cell lines.
In summary, our measurement of EVs provides a more
in depth view of the composition of the EVs of pancreatic
tumour cells, and will significantly enlarge the databases
published thus far.
The affinity purification leads to the loss of particular
protein complexes
The following results comparatively describe the differ-
ent samples with respect to the origin and functional
Table 1 Compilation of mass spectrometry analysis data
Cells Paca44 Panc1 HPDE
Sample SECR EVs crude EPCAM affi EVs lysate SECR EVs crude EVs crude EVs crude EPCAM affi EVs MFGE8 affi EVs SECR EVs crude
# IPIs 1312 627 477 1184 1187 1940 749 508 415 292 1042 1343
# GS 1147 587 449 1470 1034 1647 688 477 384 276 911 1176
Sum of peptides 22965 5336 3042 19960 24431 31624 6725 3986 1914 1085 20409 19309
Range of peptides 1-453 1-314 1-79 1-608 1-1231 1-1962 1-420 1-358 1-46 1-66 1-940 1-1570
# IPI, number of protein accession IPI; # GS, number of gene symbols; SECR, secretome samples; EVs crude, pellet after ultrafiltration and ultracentrifugation; EPCAM affi EVs, affinity purified samples using anti-EPCAM

















Figure 3 Venn diagrams compile the comparison of the mass spectrometry results from Paca44 and Panc1. Based on the IPI numbers
proteins found in affinity pure samples of Paca44 and Panc1, were matched with proteins in crude samples and the whole secretomes of
corresponding cells: 42% of the Paca44 proteins and 17% and 23% of Panc1 were exclusively measured in affinity pure samples. The number of
shared proteins in affinity purification of Paca44 and Panc1 is reduced if the anchor protein is changed.
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the gene ontological entries of the cellular compartments.
The data show that the compositions of the EV samples
differed from the secretome and also from the lysate
(Figure 4a). The crude EV samples held about twofold
more membrane proteins (near 20%) than the lysate or
secretomes. In addition, 25% of the membranous proteins
in the EV samples were measured with more than 1.5-fold
more peptides than in the secretome (see the display
“enriched EV crude” Figure 4a). Otherwise, the mitochon-
drial proteins found in the lysate were significantly lost in
the crude EV samples. Taken together, the crude EV sam-
ples represent selective parts of the cellular proteins, not
small bin bags of cells. Furthermore, the data indicated
that proteins originating from the cytoplasm, nucleus and
proteasome complex were additionally enriched in the
crude vesicle preparations. The analysis of HPDE samples
provided similar results (Additional file 1: Figure S5). In
EV preparation from HPDE the number of membranous
originated proteins also increased easily but the reduction
of extracellular proteins in secretomes is not as effective
as those in Paca44 and Panc1. There are some more
matrix and structural proteins (fibronectin, laminins, col-
lagens, tubulins), ribonucleoproteins and enzymes in the
HPDE EVs.
Based on the GOCC classification, we examined protein
groups which were reduced or enriched by the affinity
purification. The affinity purified samples of the Paca44
contained more membranous and cytoplasmic proteins
than the crude ones (Figure 4b). In contrast, theproportion of extracellular proteins in the affinity pure
samples decreased by 8%, and the number of corre-
sponding peptides by 30%. The proteins exclusively
measured in the affinity pure samples increased the
part of the membrane proteins and also the number of
proteins not merged with the GOCC entry. Similar re-
sults were obtained for the affinity purification of the
Panc1 samples, although to a weaker extent. The prote-
asome proteins have been efficiently reduced from near
10% of the peptides to less than 1% in the affinity pure
samples from both cell lines. This result fits well with
the immune detection of the proteasome subunit dis-
played in Figure 2.
To calculate the amount of “contaminants” in the crude
preparation, we analysed the proteins more frequently
found in the crude as in the secretome and the affinity
pure samples. This could be done after normalization of
the mass spectrometry data by the sum of the peptides
found in the whole sample (for details, see Materials and
Methods). Proteins (#214) lost by the affinity proced-
ure, but frequently measured in the crude samples of
the Paca44, were functionally clustered in 4 groups:
proteasomal proteins, histones, aminopeptidases and
membrane proteins such as semaphorins. Furthermore,
we found about 140 proteins in the crude exosomes,
which were partially removed or absent in the affinity
pure samples, and frequently found in the whole secre-
tome. Proteins like laminins, ribosomal proteins and the
giant protocadherin FAT1, as well as the cathepsins and
glycosidases, belong to this group.
Figure 4 Top10 gene ontology classification to cellular compartment. The percentages of the numbers of proteins (left) as well as of the
sum of the peptides measured (right) were given. a) The crude EV preparations resulted in an increased number of cytoplasmic and
membranous originating proteins and a reduction of extracellular proteins, compared to the secretome and lysate of Panc1. The “enriched crude”
was named the in silico enriched fraction, representing the proteins which were more frequently found in crude EV samples than in the
secretomes. (The analysis for HPDE samples were given in Additional file 1: Figure S5). b) By the affinity purification procedure, the number of
membranous proteins and cytoplasm originating proteins was drastically expanded and the extracellular classified proteins were reduced.
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membrane proteins were efficiently enriched by affinity
purification; however, some membrane proteins like
CD44 and CD59, also previously described as exosomal,
were reduced through the affinity protocol (Figure 5).
The amount of CD9 or TACSTD1/Epcam in the eluates
differed according to the efficiency of the procedure,
and also with the samples and antibodies used. This
suggests the existence of vesicles devoid of TACSTD1/
Epcam.
Enriched proteins in affinity pure samples: functional
implications
Clustering by functional analyses The proteins enriched
in the purified samples were filtered by the 1.3-fold
change between the normalized and corrected sumsof the peptides found from the pure to the crude
samples.
Focusing on the Paca44 affinity sample, nine functional
clusters were built by DAVID clustering from 325
enriched proteins: first group with small GTP-binding
proteins (ras family); second group with membrane
proteins (CD molecules, tetraspanins, integrins and
SLC transporters); third group with endosomal proteins
like CHMP4B (function in MVB formation) or VPS37b
(responsible for trafficking in MVBs); fourth group with
members of the armadillo-repeat containing protein
family; fifth group with SH3 domain containing pro-
teins; sixth group with integrin family proteins; seventh
group with GTPase activity proteins, like RhoF; eighth
group with ATPases; and ninth group with receptor
protein kinases like MET, EPHA2 or YES1. More than




Figure 5 Affinity purification procedure is accompanied by removal and enhancement of different proteins. Fold changes were
calculated from the normalized and corrected sum of the peptides measured for selected proteins and protein families in Paca44 affinity pure
and crude EV samples. The numbers of peptides measured in each sample were corrected and normalized as described in particular in the
Materials and Methods. Proteins, e.g. tetraspanins and CD proteins, are enriched, whereas laminins and proteasome proteins were removed.
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DAVID. We reanalysed the data with ToppGene Suite
software resulting in a small increase of the number of
clustered proteins. The data gave qualitative similar re-
sults. A comparative overview across the samples is given
in Figure 6 by the Top 5 functional clustering restricted to
the gene families and pathway categorizations. Similarities
to the Paca44 in clustering were also found for Panc1
samples (and in HPDE restricted to crude EVs), as shown
in Additional file 1: Figures S6 a, b. Small GTP binding
proteins (ras protein family), annexins, CD molecules and
other membranous proteins were enriched by purification.
Some differences were in the amount of proteins like his-
tones and some proteasomal proteins in Panc1. This may
be due to the different cell types and to the lower purifica-
tion effectiveness in Panc1 as indicated above.
Functional implications for EV-mediated carcino-
genic mechanisms Because of the high efficiency of the
affinity purification in Paca44, we focused on the proteins
found exclusively and enriched in affinity pure samples of
this cell line. The top 50 affinity enriched proteins in
Paca44 are shown in Figure 7 (and for Panc1 in Additional
file 1: Figure S7). Many membrane associated proteins
enriched in the affinity pure samples are known to have
modulatory functions in the ECM composition and
cell-cell communication. We have selected proteins,
which were overrepresented in the samples of the can-
cer cells, as compared to HPDE as model for normal
cells. The proteins Jup/gamma Catenin (CTNNG), CUB
domain containing protein (CDCP1), ecto-5′-nucleotid-
ase (CD73/NT5E), radixin (RDX), TACSTD2/Trop2,
and arrestin domain containing protein 1 (ARRDC1)
were analysed by immune blots. The specific antibodies
recognized proteins more efficiently in the affinity puresamples than in the flow through of the affinity col-
umns (Additional file 1: Figure S8).
Of special interest is the protein ARRDC1, which was
discussed as a protein responsible for the budding of
microvesicles from the plasma membrane [23,24], called
ARMMs (ARRDC1-mediated microvesicles). Otherwise,
we also found members of the ESCRTIII multiprotein
complex, like CHMP4B/VPS32B (function in multivesi-
cular body MVB formation), or ESCRTI complex, like
VPS37b (responsible for trafficking in MVBs). The lyso-
somal proteins Lamp3/CD63 and TSG101, rab7, rab11,
rab9, as well as EHDs 1–4 are also compounds of affinity
pure samples and are described as endocytotic recycling
regulators.
Are EV cancer specific proteins suitable as biomarkers and
as anchors for vesicle isolation from body fluids?
Implications for translational research
The proteomic analysis of the samples should contribute
to identify new pancreatic cancer biomarker candidates
which are preferentially released by the EVs of pancre-
atic cancer cells and are suitable in order to use them
for the isolation of cancer specific vesicles from patient
fluids. An example of proteins enriched in affinity pure
EVs of both cancer cell lines was NT5E/CD73, ecto-5′-
nucleotidase, which is a plasma membrane protein that
catalyses the conversion of extracellular nucleotides to
membrane-permeable nucleosides (especially the adenosine
release from AMP). As we expected based on the prote-
omic results, the amount of protein NT5E/CD73 was in-
creased in the affinity pure samples of Paca44, compared
to the flow through detected by immune blots (Additional
file 1: Figure S8).
The choice of NT5E/CD73 as a potential cancer bio-
marker was supported by previous findings that three out
Figure 6 Comparison of found protein accessions across the Paca44 samples with the ToppGene Suite functional analyses. The
enrichment of the CD molecules, small GTP binding proteins as well as annexins were overrepresented in the affinity pure samples, and the
released proteins derived from the ribosomes, proteasomes and tubulins were reduced. *1#899 Paca44 proteins were enriched in the secretome,
calculated by filtering with fold change (FC) crude EV/secretome < 0.7; *2#183 Paca44 proteins were enriched in exosome crude samples filtered
by FC crude EV/secretome >4.3; *3#342 Paca44 proteins were enriched in affinity purified exosomes filtered by FC affinity pure/crude >1.5 and FC
affi pure/secretome > 3; the criteria for analyses are given in Additional file 1: Figure S6.
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NT5E/CD73 in the secretomes, compared to normal epi-
thelial model cells HPDE (Klein-Scory, S. unpublished
data). Additionally, the expression of NT5E/CD73 is upreg-
ulated in pancreatic cancer on transcriptional level [25].We tested for this protein in the EV samples of other
pancreatic cancer cells and in the ascites fluid of patients.
In the EV samples derived from the model cell line HPDE
no NT5E/CD73 could be detected, whereas all tested
carcinoma cells delivered NT5E/CD73 by vesicle release
Figure 7 Top50 proteins enriched in Paca44 affinity pure EV samples in comparison to crude samples and secretomes. The groups of
proteins were selected by fold change FC affinity pure/crude >1.3 and FC affinity pure/secretome > 3, and measured with the minimal 2 peptides.
The number of peptides measured in each sample was corrected and normalized as described in the Materials and Methods. The proteins
marked with asterisks were tested by specific antibodies in the immune blots (see Additional file 1: Figure S8).
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amounts of EVs from the ascites of PDAC patients
(Figure 8b). Are epithelially derived pancreatic cancer
cells the exclusive sources of the EV specific proteins
found in the ascites of cancer patients?
In order to test whether one of the EV proteins can also
be released by other cell types associated with pancreatic
cancer, we analysed corresponding samples from human
immortalized pancreatic stellate cells hPSC in comparison
to those from carcinoma cell lines. The more common EV
proteins, like Syntenin/SDCBP and CD9, were detectable
in similar amounts in hPSC EVs as in the Paca44 derived
ones, but especially the proteins NT5E/CD73 and CDCP1,
were increased in the EVs of Paca44, more so than in EVs
of hPSCs (Figure 8c). It should be mentioned that hPSCs
are immortalized cells which, themselves, are able to form
anaplastic tumours when injected into nude mice [26].
The proof of NT5E/CD73 positive vesicles in body
fluids suggests that the EV specific proteins might be
suitable as anchors for cancer vesicles, but the source of
the vesicles is not restricted to epithelial cells.
Discussion
During early tumour development, the local tissue micro-
environment shifts to a more growth promoting state, and
tumour promoting mechanisms modulate tissue homeo-
stasis. The components released by tumour cells, as well
as by stromal cells, define this state.
Here, we describe the proteomic complexity of the
microenvironment of pancreatic tumour cells by analysing
the composition of the whole secretome and of the EVs.
Particularly the EVs are described as players in the context
of tumour stroma interaction [27]. They are containers in
which signal molecules are partially protected againstproteolysis by stroma components. The functions associ-
ated with or described for EVs are manifold [14], and are
executed by the vesicular components.
Not only proteins (as we focused on) are delivered by
EVs, but nucleic acids (mRNAs, miRNAs and tRNA frag-
ments) are also released together with the EVs [28,29]. It
should be noted that it is not clear if the nucleic acids are
really a cargo of the vesicles or only associated outside of
the vesicles. The process of the potentially selective pack-
aging of different nucleic acids into EVs is still poorly
understood. The affinity procedure described herein, to-
gether with the deep sequencing analysis of nucleic acids,
will provide further knowledge about this subject (Malas,
B. unpublished data).
Affinity purification of EVs succeeds with TACSTD1/
Epcam and enlarges the knowledge about proteomic
composition of pancreatic cancer released EVs. Here, we
used this procedure successfully for Paca44 and Panc1
to selectively catch EVs. Our analyses allow the distinc-
tion between EVs, proteasomal and ribosomal complexes
and the soluble secreted components of pancreatic can-
cer cells. This is possible through comparison of the
deep proteomic description of immune affinity purified
samples, to the whole and to fractionated samples of the
extracellular proteome.
Heterogeneity of the vesicles
Two different origins: oncosomes, ectosomes (ARMMs)
and exosomes
EVs share form, density and many characteristic cargos,
but are different in their subcellular origins and in their
size [5,10]. Some EVs bud (or are shed) directly from the
plasma membrane and are called ectosomes, microvesicles



































































































Figure 8 Release of different amounts of CD73/NT5E proteins: a) NT5E/CD73 was detected in EV samples of pancreatic carcinoma cell
lines in different amounts. No NT5E/CD73 was found in the samples of the normal model cells HPDE. The corresponding silver stained gel part
is shown for the control. b) Ascites derived from PDAC and CRC (colorectal carcinoma) patients and the conditioned medium (CM) of primary
cancer cells (isolated from ascites) were used to prepare the EV samples. Samples were tested for NT5E/CD73 by western blot. Additionally,
samples of the CRC patients were checked. c) Human pancreatic stellate cells (HPSC) also release some of the EV proteins, but in a lesser amount
than the pancreatic cancer cell line. An example of corresponding silver stained gel is given. Ly, lysate; Secr, secretome; EV, EV crude preparation.
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microvesicles, TMV, have a broader range of sizes and are
often described as a mixed population of microvesicles
sharing features described for exosomes and ectosomes
[9]. These interpretations are based on the analyses of EVs
prepared by procedures not sufficient to differentiate be-
tween vesicle populations. The ARMM release depends
on the interaction between ARRDC1 and the tetraspanin
TSG101. Exosomes, smaller than 120 nm, in restricted
view are produced by inward budding of the endosomal
membrane, accumulate as intraluminal vesicles, and are
secreted by the fusion of multivesicular bodies (MVB)
with the plasma membrane. Syntenin, Alix and ESCRT
proteins are involved in the formation and release of EVs
from the MVB [30].
The affinity pure vesicles derived from the pancreatic
cancer cells as presented in this work have the attributesof both, of plasma membrane origin (ectosomes) and of
MVB origin (exosomes).The ectosomal proteins ARRDC1
and tetraspanin TSG101 are present in affinity pure
vesicle preparations from Paca44 cells, and the EVs from
Paca44 seem to be a mixture of both vesicle types. In con-
trast to ARRDC1, the number of proteins originating from
the endosomes, lysosomes or MVBs, like charged multive-
sicular body proteins, are more frequently found in Paca44
EVs. Therefore, we conclude that the affinity pure samples
contain more exosomes than ectosomes.
Cells release different vesicle fractions with cell line
specific compositions
The proteomic analyses displayed many common charac-
teristics of the Epcam affinity purified vesicles from both
cell lines analysed here, as presented in the results section
(loss of proteasomal and ribosomal proteins, loss of ECM
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theless, the overlap in the number of proteins identified
appears moderate (in the range of 40%). This may be due,
first, to limitations in the procedure, namely, that the
small amounts of material available limit the analytical
depth. Another important reason is the individual features
of the cell line used an aspect that is not surprising in view
of the comprehensive differences in their transcriptomic
profiles, their origin and their differentiation. The cell line
Panc1 displays fewer ductal features and is described as an
epitheloid cell line (see ATCC). The low expression level
of TACSTD1/Epcam was suggested to indicate more aci-
nar properties of Panc1 cells [19]. In contrast Paca44 is
considered as a pure ductal cell line [31]. So, cell line spe-
cific components of extracellular vesicles have to be
expected.
Another important aspect is the evidence for the exist-
ence of diverse types of vesicles released from one cell
line. When an alternative protein, namely MFGE8, was
used as an anchor for immune capture of vesicles released
from Panc1 cells, both samples from Panc1 cells displayed
more pronounced differences, for example, in the relative
amount of CD9 and TACSTD1/Epcam in the eluates and
the flow through fractions as shown by Western blotting.
Moreover, when compared to the Epcam sample from
Paca44 cells the overlap among the proteins identified in
mass spectrometry is further decreased, supporting our
contention, that different types of vesicles are released.
Tauro et al. have recently published results from
affinity-purification of vesicles released from the colorectal
cancer cell line LIM1863 [32]. When we compare our pro-
tein lists with those of Tauro et al., we do not only find in
common the typical EV marker proteins like tetraspannins
and ESCRT family proteins but also the CRC enriched
proteins like ADAM10, TACSTD2/Trop2 and some integ-
rin family proteins. Interstingly, Tauro et al. have also
compared fractions immunopurified with two different
anchor molecules, namely, the colon-specific membrane
protein A33 and TACSTD1/Epcam. The samples are de-
scribed in detail and the results provide strong evidence
for the existence of separate types of vesicles.
This brings up the questions of whether, how and when
the sorting of EVs is regulated in cancer cells, and how the
packaging of vesicles is regulated. These questions remain
to be elucidated, but it appears that the ESCRT (endoso-
mal sorting complex required for transport) machinery
with the VPS or CHMPs proteins, the ARF-regulated traf-
ficking mechanisms (review in [33]) and RAB proteins
[34] play a role in these processes. Both affinity pure sam-
ples of Paca44 and Panc1 contain ESCRT proteins as well
as ARF and RAB family members.
Taken together, our data could reveal that pancreatic
cancer cells release vesicles mainly derived from endoso-
mal compartments, which we can call exosomes, and theexact composition of the vesicles varies and may be regu-
lated by cell specific mechanisms.
EVs carry functional components to modify cancer
environment
The pure preparations of the EVs allow the detailed
proteomic comparison of specific vesicular proteins with
non-vesicular protein components found in the whole
secretome. Both subproteomes contain signals or modula-
tors addressed to neighbouring cells and more distant
surrounding. The EVs, as well as the secreted soluble
components, can be bound and ingested by cells, but
EVs can also inversely absorb soluble components from
the environment.
The protein cargo of EVs and secretomes from pancre-
atic cancer cells suggests functional activities previously
shown for other cellular systems. In some publications
using rat models, EVs are suggested to establish preme-
tastatic niches in the periphery of the primary tumour
[35]. EVs can do this by preparing an attractive micro-
environment at which circulating tumour cells find pre-
ferred conditions to survive without immune attack
[36]. They can modify the ECM and carry signal modu-
lators and components of signalling pathways, sensing
the extracellular environment and modulators of im-
mune cells. The findings of our analyses most strongly
support the role of EVs in pancreatic tumours as modu-
lators of the extracellular matrix, regulators of cell-cell
contacts and cell migration. Many of the proteins fre-
quently found in pure EVs (Figure 7) are components or
regulators of the extracellular matrix (ECM), such as AD-
AMs, CD9, TROP2, CDCP1 and integrins (see above).
Another prominent protein, previously known as tumour
derived collagenase stimulating factor (TCSF) and de-
scribed as a modulator of ECM and immune response
(BSG/CD147/EMMPRIN [37]) is also a component of the
Paca44 EVs. Recently, it has been shown that CDCP1
expression is required for the attachment of colorectal
cancer cells to lung endothelial cells. CDCP1 protein is
released by the EVs and could play a role in the ex-
travasation of tumour cells to organ specific metastasis
[38].
The function of transmitting the signals from cancer
cells to the surrounding or distant environment could be
performed by protein kinases (CIT, MAP4K4, Yes1,
DDR1, WEE1, SRC) and growth factor receptors like
MET, which were measured in Paca44 EVs, together
with a high number of small G-proteins (ras, rab and
ral families).
The high amount of glycoprotein on the membranes
of the EVs could serve in the capture of therapeutic sub-
stances, so they did not effectively find the target and
became inefficient. This aspect was supported by our
findings for the EGF receptor in EVs [39]. Furthermore,
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the SLC transporters providing the import and rapid ex-
port of substances into the cells were frequent compo-
nents of the affinity pure vesicles.
One of the proposed associated functions of the EVs
was the modulation of the immune responses [40,41]. A
group of proteins specially found in affinity pure samples
was functionally clustered to regulate CXCR4-mediated
signalling, and an immune modulator is the enzyme
NT5E/CD73 which catalyses the release of adenosine [42].
The role of NT5E/CD73 was recently summarized as a
suppressor of anti cancer immune responses during car-
cinogenesis [43].Implications for translational applications
EVs isolated from various body fluids, including plasma,
malignant ascites, urine, amniotic fluid and saliva by dif-
ferent methods, were used for diagnosis [6], but the origin
of the EVs is often not clear. The definition of selective an-
chors and markers is a prerequisite for the development
of an efficient method to isolate EVs and biomarkers.
Consequently, our aim was to propose anchor proteins
to catch EVs deriving from pancreatic cancer cells. Previ-
ous studies using the anchor protein TACSTD1/Epcam
showed the amplified release of EVs into the body fluids
of ovarian or lung cancer patients [44,45]. The low effi-
ciency of purification using the anchor TACSTD1/Epcam
for Panc1 showed that TACSTD1/Epcam could not be
considered to be a common anchor for PDAC derived
vesicles. The isolation of EVs is restricted to TACSTD1/
Epcam expressing cells. Furthermore, it is suggested that
this protein is partially processed in body fluids [46]. The
other anchor protein, MFGE8, expression also varied in a
broad range across the PDAC cell lines, therefore, it is not
useful to efficiently isolate pancreatic cancer specific EVs
from the body fluids of PDAC patients.
The membrane protein CD73/NT5E was initially the
focus in defining pancreatic cancer specific markers. Al-
though the pancreatic carcinoma cells express and re-
lease more NT5E/CD73 than the model cell line HPDE,
the specificity of this protein for carcinoma cells is lim-
ited: for example, the immortalized human pancreatic
stellate cells hPSC (and mesenchymal cells) release this
protein. Additionally, we found this protein in the ascites
of CRC patients. This confirmed that NT5E/CD73 is a
component of EVs derived from colorectal cancer cells
[45]. Furthermore, its expression is up regulated in other
cancer types, such as melanoma, breast and colorectal
cancer, and its over expression is correlated with poor
prognosis in CRC [47]. The analysis of this candidate il-
lustrates that the EV proteins described in the catalogue
herein can be measured in primary material, i.e. in body
fluids, and thus provides proof of principle for theimportance to include EV derived proteins into bio-
marker discovery approaches.
Conclusion
In summary, the affinity purification, together with the
deep proteomic analyses of EVs, provided many new com-
ponents not previously described for EVs derived from
pancreatic tumour cells. The data herein clarify the com-
position of EVs from pancreatic cancer cells in contrast to
other released proteins, and discuss these proteins in the
context of tumour stroma interactions.
Materials and methods
Cell culture and ascites fluid collection
The human pancreatic adenocarcinoma cell line, Paca44,
was kindly provided by M. Löhr (Heidelberg, Germany);
Panc1 and BxPc3, MiaPaca2 and HPSC (human pancre-
atic stellate cells) were obtained from the American Type
Culture Collection (ATCC, Rockville, MD); and A818-4
cells were obtained from our lab (W.S.). The cells were
maintained in supplemented Dulbecco’s Modified Eagle’s
Medium (DMEM). Human pancreatic ductal epithelial
(HPDE) cells were kindly provided by M.S. Tsao (Toronto)
and cultured in defined Keratinocyte-SFM (KFSM, Life
technology), as described previously [39].
The collection of ascites was done in the German univer-
sity hospital, Knappschaftskrankenhaus Bochum, during
patient therapy. Ascites was obtained from patients diag-
nosed with pancreatic cancer or colorectal cancer. All pa-
tients provided written informed consent for the use of the
samples in research, as approved by the ethics board of the
medical faculty of the University of Bochum (http://www.
ruhr-uni-bochum.de/ethik/download/Deklaration_Helsinki
_2008_engl..pdf). Primary carcinoma cells were isolated
from the ascites by centrifugation, and the non-carcinoma
cells died within one week. The lymphocytes were lost dur-
ing the first cell culture procedures. The remaining cells
were cultured in DMEM containing 10% foetal calf serum
and supplements.
Preparation of secretome and extracellular vesicle
fractions
Secretome preparation was performed as previously de-
scribed [39]. Cells were grown in standard medium until
they reached a confluency of approximately 60-70%. The
carcinoma cell lines were then washed three times with
DMEM and incubated in a serum-free medium with sup-
plements for 16 hours. This protocol did not measurably
increase the rate of cell death, as determined by Casy
(Schärfe System, Germany). Afterwards, the ice cooled
conditioned media was centrifuged (200 g, 10 min) and
passed through 0.2 μm pore filters. A protease inhibitor
cocktail was added. The secretome samples were concen-
trated by ultrafiltration (Amicon Ultra 3 K, Millipore,
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mined in a Bradford protein assay.
The crude preparation of the EV fraction samples was
performed as described by van Niel et al. with modifica-
tions [48]. In brief, the conditioned media cleared from
the cells and cell debris as described above were sub-
jected to ultrafiltration (Amicon Ultra 100 K, Millipore,
Schwalbach, Germany) and subsequent ultracentrifugation
was performed at 120,000 × g for 90 min at 4°C using a
T-890 titanium fixed angle rotor (Sorvall, Langenselbold,
Germany). The resuspended pellets were called crude EVs
and were stored at −80°C. The preparation of the ascites
cell derived EVs was carried out as described for the estab-
lished pancreatic carcinoma cell lines.
Density gradient centrifugation
A 15 ml OptiPrep gradient (Axis–Shield, Oslo, Norway)
of 5 layers was prepared following the protocol of the
manufacturer. The freshly prepared ultracentrifugation
pellets were suspended in TBS (50 mM TrisHCl,
135 mM NaCl, 2 mM EDTA pH 7.2) and were added to
the top of the gradient. After 18 h of centrifugation in the
Surespin 630 rotor of a Sorvall centrifuge at 177,000 × g,
14 fractions of 1 ml each were taken from the top. The
fractions were subsequently concentrated by ultrafiltration
(Amicon Ultra 100 K, Millipore, Schwalbach, Germany)
and analysed by western or dot blots.
Affinity purification of EVs/exosomes
According to the description in [49], ultracentrifugation
pellets, called the crude EV preparation, were incubated
with 50 μl TACSTD1/EPCAM coated magnetic beads
and separated with μMac columns as described by the
manufacturer (Miltenyi Biotech Inc., Bergisch Gladbach,
Germany). The isolations of Panc1 exosomes were add-
itionally carried out with anti-MFGE8 or anti-CD63 for
1 hour. Anti-rabbit or anti-mouse beads (50 μl) were
added. The magnetically labelled samples were separated
by Miltenyi μMac columns as described by the manufac-
turer (Miltenyi Biotech Inc, Bergisch Gladbach, Germany).
After three washes, the columns were removed from the
magnet, and the magnetically labelled samples were re-
ceived using PBS or NP40 containing buffers as indicated.
The eluates (and the concentrated flow through of the col-
umns) were analysed.
Immune detection
The samples, as indicated, were separated on NuPAGE
gradient gels (4–12%), and the proteins were trans-
ferred to a PVDF membrane in a semi-dry blotting
procedure. The following primary antibodies were
used: Alix (PDCD6IP; Santa Cruz Biotechnology Inc.,
Santa Cruz, USA), Syntenin (SDCBP; Synaptic Systems,
Göttingen, Germany), Lamp3 (CD63; MX-49.129.5 SantaCruz Biotechnology Inc.,Santa Cruz, USA), CDCP1
(Cell Signaling Technology, Inc., Danvers, USA), CD9
(Sigma-Aldrich Chemie GmbH, Munich, Germany),
MFGE8 (lactadherin, R&D Systems, Wiesbaden, Germany),
CD73/NT5E (Sigma-Aldrich ChemieGmbH, Munich,
Germany), TACSTD1/Epcam (Biomol, Hamburg, Germany),
TACSTD2/Trop2(Abcam, Cambridge, UK), radixin (RDX;
Abcam, Cambridge, UK) and arristin (ARRDC1; Abcam,
Cambridge, UK). The primary antibodies were detected
with species-specific secondary antibodies (goat, rabbit or
mouse), each conjugated with a fluorescent dye, Alexa 680
(Invitrogen, Darmstadt, Germany), IRDye 800 (Biomol,
Hamburg, Germany) or DyLight™ 800 (Thermo Scientific,
Bonn, Germany).
For the dot blot analyses, 3 μl of each fraction were
spotted on a nitrocellulose membrane (Millipore,
Germany). After the spots had dried, the membrane
was blocked and incubated with primary antibodies
(anti-Syntenin, anti-CD63/lamp3). The values were
calculated by integrated intensities measured using the
Odyssey 2.1 software program (LI-COR, USA).
Illustration of the extracellular vesicles by TEM analysis
and PKH67 staining
An aliquot (5 μl) of freshly prepared ultracentrifugation
pellets was deposited on Formvar coated grids, and left
to adsorb for 30 min. The samples were subsequently
negatively contrasted with 1% uranylacetate for 5 min.
The grids were viewed under TEM. This procedure
followed the protocol described by [50]. The PKH67
green fluorescent cell linker kit (Sigma-Alrich Chemie
GmbH, Munich, Germany) was used to label the EVs ac-
cording to the instruction manual and as described in
[51].
Mass spectrometric analysis
Mass spectrometric analyses are described in [39]. The
samples from each cell line and the preparation were
separated on 1D NuPAGE gradient gels (4-12% acryl-
amide, Bis-Tris with MES running buffer; Invitrogen,
Darmstadt, Germany). Each lane was cut into 2 mm
wide slices as displayed in Additional file 1: Figure S9,
and the gel slices were subjected to in-gel digestion with
trypsin (Promega, Madison, WI). The supernatant from
the tryptic digestion and from the four extraction steps
was combined, evaporated and dissolved in H2O/FA,
99.9/0.1 v/v.
A nanoscale LC-MS analysis of the tryptic peptides
was performed using the nanoACQUITYUPLC system
(Waters, Eschborn, Germany) which was coupled online
to an LTQ Orbitrap XL mass spectrometer (Thermo Sci-
entific, Bremen, Germany). Data were acquired by scan
cycles of one FTMS scan with a resolution of 60,000 and
a range from 370 to 2,000 m/z, in parallel with six MS/
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ions. The MS/MS spectra were searched with the MAS-
COT search engine (Matrix Science, London, UK; version
2.2) against the human MSIPI database. The peptide mass
tolerance for the database searches was set to 5 ppm, and
the fragment mass tolerance was set to 0.5 Da. Further-
more, the proteins were considered to be identified if
more than one unique peptide had an individual ion score
exceeding the MASCOT identity threshold (ion score cut-
off of 22–23). Identification under the applied search
parameters refers to a False Discovery Rate (FDR) < 3.5%
and a match probability of p < 0.05, where p is the prob-
ability that the observed match is a random event.
Each slice was analysed separately and MS/MS data
were not merged prior to the protein database search to
maintain the information about the molecular weight of
each protein, peptide matches and identification score.
In this way, the protein catalogues from the human pan-
creatic cell secretomes, lysates, crude extracellular vesi-
cles (exosomes) and affinity pure EVs were assembled.
In silico comparison of proteomics data
Additional file 2 was compiled for all identified proteins
using the IPI number, protein score, protein description
and the number of identified peptides (peptide matches).
Normalization of the label free mass spectrometry data
was performed according to [52]. The number of peptides
of a protein in the different samples was corrected using
the sum of the measured peptides. For example, for the
Paca44 cell line, 22,965 peptides were found in all slices of
the secretome, 5,336 peptides in the crude EV sample, and
3,042 peptides in the affinity pure samples of this cell line
(Table 1). To compare these with the Paca44 secretome,
the number of matches/peptides was normalized using the
correction factors between the sum of the measured pep-
tides corrected by a factor of 4.3 for the Paca44 crude and
7.5 for the Paca44 affinity pure samples. The normalizations
were done over the samples per cell line.
To describe more deeply the entirety of proteins mea-
sured in the affinity pure samples, we analysed the protein
lists with two functional classification tools (DAVID
software package and ToppGene Suite software). For the
DAVID analysis (database version 6, 2009) [53] and for the
ToppGene Suite software [54], the IPI numbers of the
proteins were used and analysed against whole entries in
the database. With the ToppGene Suite software, the Top5
results of the clustering were displayed across the samples.
The comparison of the mass spectrometry data with the
Vesiclepedia database was performed with downloadable
files from the homepage, Vesiclepedia 1.1 (http://microvesi-
cles.org/download; [22]) filtered for human and aliases of
the gene symbols converted by DAVID. The ExoCarta
database 4.1 was downloaded from www.exocarta.org [15].Additional files
Additional file 1: S1-S9 compiled in a single PDF. S1. Vesicular character
of the crude EV preparations: a) Only the treatment with detergent
containing buffers led to the passage of EV proteins through a 100 kDa
cut off filter. b) The PKH67 green fluorescent cell linker kit (Sigma-Alrich
Chemie GmbH, Munich, Germany) was used to label the EVs according
to the instruction manual and as described in [54]. Ultracentrifugation
pellets were suspended in 100 μl tris based saline with exosome
depleted foetal calf serum; 10 μl anti CD326 FITC was added, and
incubated 10–30 min at 4°C. By filling up to 6 ml TBS, the samples were
washed, then centrifuged at 120,000 g for 1 h. The supernatant was
removed completely and the pellets were resuspended in 0.5 ml TBS and
analysed with Facs. S2. Selection of cell lines and anchor proteins to isolate
pure EV fractions. a) Paca44 contained the highest amount of TACSTD1/EPCAM
protein, whereas Panc1 showed a significantly lower TACSTD1/EPCAM
detection level in the exosomes. The EV preparations were checked for
Syntenin and the proteasome subunits (PSU). b) In contrast to the other
pancreatic cells, MFGE8ishighly expressed only in Panc1 and detectable also in
HPDE in the crude EV preparation, but not sufficient for effective affinity
purification of HPDE EVs. S3. Control experiments for affinity purification. Epcam
proteins are only detectable in eluates, if the inserted sources containedEVs.
S4. Venn diagram illustrate the comparison of secretomes and EVs Paca44,
Panc1 and HPDE samples (a,b ) The crude EV proteins analyses enlarge the
number of proteins found by secretome measurements and deepened the
view of released proteins by pancreatic cells. The secretomes of the three
different cell lines share nearly 50% of proteins. However, the crude EV
comparison is influenced by the different number of measured proteins of
different samples. The venn diagram of Panc1 affinity pure samplesusing
EPCAM or MFGE8 as anchor proteins (c) shows that both affinity pure samples
share 173 proteins, which comprise 41% and 59% ofeach sample. S5. S5HPDE
secretome and crude EV classified to cellular compartment by gene ontology
(TOP 10). The percentages of the numbers of proteins (left) as well as of the
sum of the peptides measured (right) were given. In EV preparation from HPDE
the number of membranous originated proteins also increased easily but the
reduction of extracellular proteins in secretomes is not as effective as in Paca44
and Panc1. S6. TOP5 ToppGene Suite categorizations: Lists of proteins of
samples from Panc1 (a) and from HPDE (b) were subjected to the functional
enrichment analysis by ToppGene Suite. Cut offs of the categorization as well as
the compilations of the results are given. S7. Top 50 proteins enriched in Panc1
affinity pure EV samples in comparison to crude samples and secretomes
filtered by FC affi pure/crude EVs > 1.3 and FC affi pure EVs/secretome > 3. The
number of peptides measured in each sample was corrected and normalized
as described in the Materials and Methods. Marked by stars are proteins also
included in the Top 50 affinity pure Paca44 EVs. S8. Proteins more frequently
measured by mass spectrometry in affinity pure samples of Paca44 were
analysed by immunoblot using specific antibodies. S9. Images of gels with
slices: Protein samples of each cell line were resolved in NuPAGE gradient gels
4-20% (life technologies). After electrophoresis, the gels were stained with an
MS compatible Krypton staining procedure according to the manufacturer’s
protocol(Thermo Scientific, Bonn, Germany). The gel pictures were drawn using
a Licor Odyssee 680 nm scanner. The gels were cut in 29slices and 15 slices as
indicated. Each gel piece was separately prepared and analysed by mass
spectrometry.
Additional file 2: Extended tables of mass spec data as an excel file.
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